
AlloSeq Nano delivers rapid, high‑resolution HLA and ABO genotyping in a single assay through a streamlined, long‑read workflow designed for transplant and donor typing laboratories.


CareDx, Inc. (NASDAQ:CDNA) — The

<p xmlns="http://www.w3.org/1999/xhtml">
<i xmlns="http://www.w3.org/1999/xhtml">AlloSeq Nano delivers rapid, high‑resolution HLA and ABO genotyping in a single assay through a streamlined, long‑read workflow designed for transplant and donor typing laboratories.</i>

</p><p xmlns="http://www.w3.org/1999/xhtml">
CareDx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CDNA">CDNA</a>) — The Transplant Company&#x2122;, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO blood type genotyping solution, at the European Federation for Immunogenetics (EFI) Conference 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml">
AlloSeq Nano is an innovation developed by CareDx to deliver high‑resolution HLA genotyping in under three hours with streamlined long‑read library prep workflow, rapid assay turnaround, robust performance, and enhanced resolution.

</p><p xmlns="http://www.w3.org/1999/xhtml">
In early access testing, Alloseq Nano's single-step amplification and prep workflow required approximately 45 minutes of hands‑on time to assay eleven HLA loci plus ABO in a single test. The assay's elegant probe redundancy helps minimize allele dropout, while long-read sequencing reduces phasing ambiguities, enhancing overall performance and accuracy.

</p><p xmlns="http://www.w3.org/1999/xhtml">
AlloSeq Nano expands CareDx's pre‑transplant Lab Products portfolio, alongside AlloSeq Tx and QTYPE<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup>, to support a broader range of laboratory throughput requirements and use cases.

</p><p xmlns="http://www.w3.org/1999/xhtml">
To introduce AlloSeq Nano, CareDx will host a satellite symposium at EFI 2026 on Thursday, April 23, from 13:00–14:00 BST, at the Edinburgh Congress Centre, Sidlaw Auditorium. The symposium will feature scientific and educational discussions related to AlloSeq Nano and CareDx's transplant diagnostics portfolio.

</p><p xmlns="http://www.w3.org/1999/xhtml">
CareDx will also present multiple abstracts at EFI 2026 reflecting scientific engagement across laboratory, clinical, and technical dimensions of transplant diagnostics. Accepted abstracts include presentations featuring AlloSeq cfDNA in kidney and lung transplant settings, as well as a presentation featuring QTYPE<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;,</sup> highlighting rapid ABO genotyping in combination with HLA typing.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Lab Products Business Update</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
CareDx announced on April 15, 2026 that it entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific, which is expected to close by the end of the third quarter of 2026. CareDx's Lab Products business consists of IVD (in vitro diagnostic) PCR kits for rapid deceased donor HLA (human leukocyte antigen) typing, IVD NGS-based (next-generation sequencing) kits for transplant recipient HLA typing globally, including AlloSeq Nano; and IVD NGS-based monitoring assays for solid organ and stem cell transplant recipients outside of North America.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About CareDx</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company's integrated solutions include non‑invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics‑based information for transplant patients. For more information, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.caredx.com%2F&amp;esheet=54518377&amp;newsitemid=20260420549411&amp;lan=en-US&amp;anchor=www.caredx.com&amp;index=1&amp;md5=664d98d605534bd927115e994f2a005b" shape="rect">www.caredx.com</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release includes forward-looking statements related to CareDx including statements regarding the potential benefits and results that may be achieved with AlloSeq Nano. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of AlloSeq Nano, general economic and market factors, and other risks discussed in CareDx's filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by CareDx with the SEC on February 25, 2026, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

</p><p xmlns="http://www.w3.org/1999/xhtml">
AlloSeq Nano, AlloSeq cfDNA, and QTYPE are available as CE-IVD and Research Use Only (RUO). RUO products are not to be used for diagnostic procedures. For local regulatory status, please contact CareDx. AlloSeq is a trademark or registered trademark of CareDx Inc. or its subsidiaries in the US or other countries. AlloSeq is a registered trademark with the US Patent and Trademark Office. &#xA9; 2026 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260420549411r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260420549411/en/" rel="nofollow">https://www.businesswire.com/news/home/20260420549411/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">CareDx, Inc. 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Media
<br xmlns="http://www.w3.org/1999/xhtml"></br>Natasha Moshirian Wagner
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:nwagner@CareDx.com" shape="rect"><b xmlns="http://www.w3.org/1999/xhtml">nwagner@CareDx.com 
</b></a><b xmlns="http://www.w3.org/1999/xhtml"><br xmlns="http://www.w3.org/1999/xhtml"></br>
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Investor Relations
<br xmlns="http://www.w3.org/1999/xhtml"></br>Caroline Corner
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:investor@CareDx.com" shape="rect"><b xmlns="http://www.w3.org/1999/xhtml">investor@CareDx.com</b></a>

</p>

CDNA

CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing

CareDx Introduces AlloSeq Nano to Enhance Genotyping Solutions

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>AlloSeq Nano delivers rapid, high‑resolution HLA and ABO genotyping in a single assay through a streamlined, long‑read workflow designed for transplant and donor typing laboratories.


CareDx, Inc. (NASDAQ:CDNA) — The</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>CareDx has introduced AlloSeq Nano, a cutting-edge genotyping solution that achieves high-resolution results in under three hours. This innovation expands CareDx&#039;s Lab Products portfolio and is positioned to attract new business opportunities ahead of the company&#039;s planned divestiture of the Lab Products segment by Q3 2026.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>CareDx launched AlloSeq Nano for rapid HLA and ABO genotyping.</li><li>AlloSeq Nano provides high-resolution genotyping in under three hours.</li><li>The product enhances CareDx&#039;s lab portfolio and supports diverse lab needs.</li><li>CareDx plans to divest its Lab Products business by Q3 2026.</li><li>The company will showcase AlloSeq Nano at the EFI Conference 2026.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>CareDx, Inc. (CDNA)</strong>: CareDx is expanding its product offerings with AlloSeq Nano.</li><li><strong>EuroBio Scientific (N/A)</strong>: EuroBio Scientific is set to acquire CareDx&#039;s Lab Products business.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under &#039;Corporate Developments&#039; as it involves new product offerings and strategic divestitures. Such moves could positively impact CareDx&#039;s market position and overall financial health.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>AlloSeq Nano&#039;s launch may increase lab testing orders and revenue.</li><li>CareDx&#039;s portfolio expansion could position them advantageously in the transplant market.</li><li>The upcoming lab products divestiture may unlock capital for strategic investments.</li><li>Success at EFI Conference could enhance market perception and stock value.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>AlloSeq Nano delivers results under three hours and requires minimal hands-on time.</li><li>The assay can test for eleven HLA loci and ABO in a single test.</li><li>CareDx plans to divest its Lab Products business by Q3 2026.</li><li>AlloSeq Nano was introduced at the EFI Conference 2026 on April 23.</li><li>The conference provides a platform for broader recognition of CareDx&#039;s offerings.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider buying CDNA as AlloSeq Nano could drive revenue growth in the next year.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml">
<i xmlns="http://www.w3.org/1999/xhtml">AlloSeq Nano delivers rapid, high‑resolution HLA and ABO genotyping in a single assay through a streamlined, long‑read workflow designed for transplant and donor typing laboratories.</i>

</p><p xmlns="http://www.w3.org/1999/xhtml">
CareDx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CDNA">CDNA</a>) — The Transplant Company&#x2122;, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO blood type genotyping solution, at the European Federation for Immunogenetics (EFI) Conference 2026.

</p><p xmlns="http://www.w3.org/1999/xhtml">
AlloSeq Nano is an innovation developed by CareDx to deliver high‑resolution HLA genotyping in under three hours with streamlined long‑read library prep workflow, rapid assay turnaround, robust performance, and enhanced resolution.

</p><p xmlns="http://www.w3.org/1999/xhtml">
In early access testing, Alloseq Nano's single-step amplification and prep workflow required approximately 45 minutes of hands‑on time to assay eleven HLA loci plus ABO in a single test. The assay's elegant probe redundancy helps minimize allele dropout, while long-read sequencing reduces phasing ambiguities, enhancing overall performance and accuracy.

</p><p xmlns="http://www.w3.org/1999/xhtml">
AlloSeq Nano expands CareDx's pre‑transplant Lab Products portfolio, alongside AlloSeq Tx and QTYPE<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup>, to support a broader range of laboratory throughput requirements and use cases.

</p><p xmlns="http://www.w3.org/1999/xhtml">
To introduce AlloSeq Nano, CareDx will host a satellite symposium at EFI 2026 on Thursday, April 23, from 13:00–14:00 BST, at the Edinburgh Congress Centre, Sidlaw Auditorium. The symposium will feature scientific and educational discussions related to AlloSeq Nano and CareDx's transplant diagnostics portfolio.

</p><p xmlns="http://www.w3.org/1999/xhtml">
CareDx will also present multiple abstracts at EFI 2026 reflecting scientific engagement across laboratory, clinical, and technical dimensions of transplant diagnostics. Accepted abstracts include presentations featuring AlloSeq cfDNA in kidney and lung transplant settings, as well as a presentation featuring QTYPE<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;,</sup> highlighting rapid ABO genotyping in combination with HLA typing.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Lab Products Business Update</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
CareDx announced on April 15, 2026 that it entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific, which is expected to close by the end of the third quarter of 2026. CareDx's Lab Products business consists of IVD (in vitro diagnostic) PCR kits for rapid deceased donor HLA (human leukocyte antigen) typing, IVD NGS-based (next-generation sequencing) kits for transplant recipient HLA typing globally, including AlloSeq Nano; and IVD NGS-based monitoring assays for solid organ and stem cell transplant recipients outside of North America.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About CareDx</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company's integrated solutions include non‑invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics‑based information for transplant patients. For more information, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.caredx.com%2F&amp;esheet=54518377&amp;newsitemid=20260420549411&amp;lan=en-US&amp;anchor=www.caredx.com&amp;index=1&amp;md5=664d98d605534bd927115e994f2a005b" shape="rect">www.caredx.com</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release includes forward-looking statements related to CareDx including statements regarding the potential benefits and results that may be achieved with AlloSeq Nano. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of AlloSeq Nano, general economic and market factors, and other risks discussed in CareDx's filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by CareDx with the SEC on February 25, 2026, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

</p><p xmlns="http://www.w3.org/1999/xhtml">
AlloSeq Nano, AlloSeq cfDNA, and QTYPE are available as CE-IVD and Research Use Only (RUO). RUO products are not to be used for diagnostic procedures. For local regulatory status, please contact CareDx. AlloSeq is a trademark or registered trademark of CareDx Inc. or its subsidiaries in the US or other countries. AlloSeq is a registered trademark with the US Patent and Trademark Office. &#xA9; 2026 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260420549411r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260420549411/en/" rel="nofollow">https://www.businesswire.com/news/home/20260420549411/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">CareDx, Inc. 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Media
<br xmlns="http://www.w3.org/1999/xhtml"></br>Natasha Moshirian Wagner
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:nwagner@CareDx.com" shape="rect"><b xmlns="http://www.w3.org/1999/xhtml">nwagner@CareDx.com 
</b></a><b xmlns="http://www.w3.org/1999/xhtml"><br xmlns="http://www.w3.org/1999/xhtml"></br>
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Investor Relations
<br xmlns="http://www.w3.org/1999/xhtml"></br>Caroline Corner
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:investor@CareDx.com" shape="rect"><b xmlns="http://www.w3.org/1999/xhtml">investor@CareDx.com</b></a>

</p>

CareDx has introduced AlloSeq Nano, a cutting-edge genotyping solution that achieves high-resolution results in under three hours. This innovation expands CareDx's Lab Products portfolio and is positioned to attract new business opportunities ahead of the company's planned divestiture of the Lab Products segment by Q3 2026.

CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News